EFG Asset Management North America Corp. Has $8.25 Million Holdings in Axon Enterprise, Inc $AXON

EFG Asset Management North America Corp. lessened its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 9.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,500 shares of the biotechnology company’s stock after selling 1,201 shares during the quarter. Axon Enterprise accounts for approximately 1.1% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 12th biggest holding. EFG Asset Management North America Corp.’s holdings in Axon Enterprise were worth $8,252,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in AXON. Sumitomo Mitsui Trust Group Inc. grew its stake in Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after purchasing an additional 5,953 shares in the last quarter. Wealthedge Investment Advisors LLC raised its stake in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock worth $997,000 after purchasing an additional 775 shares in the last quarter. Jaffetilchin Investment Partners LLC boosted its holdings in shares of Axon Enterprise by 11.7% in the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 5,938 shares of the biotechnology company’s stock valued at $4,916,000 after buying an additional 624 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Axon Enterprise by 3.5% in the 2nd quarter. Vanguard Group Inc. now owns 8,937,260 shares of the biotechnology company’s stock valued at $7,399,515,000 after buying an additional 305,252 shares during the last quarter. Finally, Duncker Streett & Co. Inc. grew its stake in shares of Axon Enterprise by 3.2% in the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock valued at $12,006,000 after buying an additional 448 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $605.07 on Tuesday. The stock has a market cap of $47.75 billion, a PE ratio of 191.48, a P/E/G ratio of 19.30 and a beta of 1.41. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The firm has a 50-day moving average of $577.40 and a 200-day moving average of $674.32. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm’s revenue was up 30.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.45 earnings per share. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on AXON shares. Royal Bank Of Canada initiated coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They set an “outperform” rating and a $860.00 price target on the stock. Northcoast Research upgraded shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective on the stock in a research note on Tuesday, January 6th. Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group lowered their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $805.71.

Insider Activity at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the completion of the sale, the chief executive officer directly owned 3,110,997 shares of the company’s stock, valued at approximately $1,717,021,464.24. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the transaction, the president directly owned 249,502 shares in the company, valued at approximately $137,874,805.20. This represents a 7.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 60,540 shares of company stock valued at $34,684,738 in the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.